



13 September 2021

Creso Pharma secures new purchase orders for human health products and expands European market presence

Highlights:

- **Two purchase orders ("PO") secured from import/export partner MHG GmbH, Switzerland (MHG) valued at CHF230,000 (A\$337,577ⁱ)**
- **MHG are a Swiss company with access to over 3,500 international points of sale**
- **Highlights the scale up of Creso Pharma's human health business**
- **POs are comprised of cannaQIX® hemp seed oil lozenges and cannaQIX® 50mg lozenges**
- **Products to be supplied to MHG immediately and exported into new European countries strengthening the Company's geographic footprint**
- **POs represents an important milestone to further strengthen Creso Pharma's export business**

Creso Pharma Limited (ASX:CPH, FRA:1X8, OTC: COPHF) ('Creso Pharma' or 'the Company') is pleased to advise that it has secured two new purchase orders ("PO") with a combined value of CHF230,000 (A\$337,577ⁱ) from Swiss based health products distributor MHG GmbH ("MHG") for its cannaQIX® hemp seed oil lozenges and cannaQIX® 50 lozenges. The new purchase orders will allow Creso Pharma to broaden its European market presence.

MHG is a health services company, focused on the import and export of health and wellbeing products. The group was established in 2016 and is based in Zug, Switzerland. MHG has extensive expertise in pharmaceutical product distribution and an established market presence with over 3,500 international points of sale.

Creso Pharma will deliver the products as soon as possible from its available stock. The products will be sold through MHG's sales channels into a range of other countries including Macedonia, Albania, Serbia, and Croatia amongst others.

The POs represent an important milestone and underpin geographic expansion initiatives for Creso Pharma's human health business into a range of new countries. Both parties will continue to work collaboratively to broaden Creso Pharma's international footprint.

Creso Pharma and MHG are also progressing discussions to extend additional purchase orders for the Company's animal health products, which could further increase Creso Pharma's global footprint and add to its growing revenue profile.

Management Commentary:

CEO of Swiss International Operations, Mr Jorge Wernli said: *"We are very pleased to have secured these POs from MHG and it is a clear sign that our export business for human health products is beginning to scale up again. The POs will add to the Company's growing revenue line, as well as allow Creso Pharma to expand into new countries."*

"This is a key milestone on our journey and commitment to strengthening Creso Pharma's export business and geographic expansion, which we anticipate will unlock value for shareholders."



Images: cannaQIX® hempseed oil based pack with two blisters of 24 lozenges and the cannaQIX® 50mg pack with two blisters of 24 lozenges

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@cresopharma.com

P: +61 (0) 497 571 532

Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About MHG

MHG GmbH is a Health Services import and export company based in Zug, Switzerland. The company is registered in the Swiss Commercial Registry and has been operating since 2016. The company has access to over 3,500 point of sales in European countries.

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It



has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.

¹ CHF to AUD exchange rate of \$1.47